Nothing said here yet.
to join the conversation.
| LINK WILLIAM J PHDDirector | Sell | 11,675 | $914.5K | Tue, Sep 15 |
| LINK WILLIAM J PHDDirector | Sell | 759 | $60.0K | Tue, Sep 15 |
| LINK WILLIAM J PHDDirector | Sell | 66 | $5.3K | Tue, Sep 15 |
| Azamian Bobak R.President/CEO and Board Chair | Sell | 7,100 | $640.9K | Fri, Sep 4 |
| Lin Elizabeth YeuChief Medical Officer | Sell | 5,386 | $484.7K | Fri, Sep 4 |
| Lin Elizabeth YeuChief Medical Officer | Sell | 5,387 | $457.9K | Fri, Sep 4 |
| Neervannan SeshadriChief Operating Officer | Sell | 4,564 | $387.9K | Fri, Sep 4 |
| Azamian Bobak R.President/CEO and Board Chair | Sell | 2,900 | $264.7K | Fri, Sep 4 |
| Lin Elizabeth YeuChief Medical Officer | Sell | 1,590 | $143.1K | Fri, Sep 4 |
| Lin Elizabeth YeuChief Medical Officer | Sell | 1,590 | $135.2K | Fri, Sep 4 |
| Azamian Bobak R.President/CEO and Board Chair | Sell | 10,000 | $800.6K | Wed, Sep 2 |
| Lin Elizabeth YeuChief Medical Officer | Sell | 5,387 | $431.0K | Wed, Sep 2 |
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap side.
XDEMVY sales hit $173.9M with 69% growth as Tarsus expands into retinal diseases.
Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol,…
Strong commercial momentum drives raised guidance as Tarsus positions for a diversified ophthalmology portfolio.
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc.